News

What is the role of oncology nurses as artificial intelligence technologies become a clinical reality?

The FDA has approved acalabrutinib plus venetoclax in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

WVU Medicine has begun treating patients in the first clinical trial to explore the use of subcutaneous blinatumomab in patients with CD19-positive MPAL.

FDA fast-tracks trispecific IBI3003, reviews iberdomide combo, and expands Yescarta use.

Emely Alfaro, RN, MSN, CNS, OCN, shares exclusive insights on her cancer-specific research on patients with difficult IV access.

The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment.

A device delivering tumor treating fields has been approved for concurrent treatment with gemcitabine and nab-paclitaxel for patients with LA-PAC.

Emese Zsiros, MD, PhD, FACOG, discusses managing paclitaxel toxicity and the role of pembrolizumab maintenance in treating platinum-resistant ovarian cancer.

Patients with NRG1 fusion-positive cholangiocarcinoma who received zenocutuzumab had a favorable response rate in the phase 1/2 eNRGy trial.

New clinical data highlight the impact of infusion timing on NSCLC survival, alongside updated ASCO guidelines and FDA RMAT status for inhaled KB707.

The FDA approved IV and subcutaneous pembrolizumab with paclitaxel with or without bevacizumab for patients with platinum-resistant ovarian cancers.

In a clip from the latest Onc Nurse on Call episode, social worker Kelly Grosklags explains that emotions strengthen the connection between patient and clinician in oncology.

Practical examples of advanced practice provider–led initiatives that improve safety, symptom management, and patient outcomes.

The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk severe or fatal toxicities.

Investigator Elizabeth Lee, MD, discusses efficacy and safety data for rinatabart sesutecan in patients with endometrial cancer.

A look at the current state of cancer, from survival rates to federal research budgets.

Kelly Grosklags, LICSW, BCD, FAAGC, FT, shares advice for dealing with grief in oncology nursing, from treating patients in denial to showing emotion in front of them.

Dato-DXd has been given priority review for the treatment of patients with unresectable/metastatic triple-negative breast cancer.

Multicancer early detection tests may expand screening options, but does the benefit outweigh the uncertainties?

In a world of unfamiliarity and uncertainty, patient advocates help guide those with cancer through challenging diagnoses and the decisions that come with them.

Nurses are called to honor Alex Pretti’s memory through compassion and action.

The FDA approved a larger vial size of nelarabine for the treatment of pediatric and adult patients with T-ALL and T-LBL.

Updates in ovarian cancer include multiple fast track designations and breakthrough therapy status for new drugs in the clinical space.

The FDA approved subcutaneous daratumumab/VRd in patients with newly diagnosed multiple myeloma who are not eligible for ASCT. Here’s what you should know.

Plus, a phase 1 breast cancer vaccine, updated NCCN guidelines, and a combination with standard-of-care potential in triple-negative breast cancer.

The frontline combination of nivolumab and ipilimumab demonstrated long-term safety and efficacy in patients with unresectable hepatocellular carcinoma.

Kelly Grosklags, LICSW, BCD, FAAGC, FT, shares insights for dealing with grief as an oncology clinician.

Chemoradiotherapy led to OS and RFS benefit in high-risk patients with chemoradiotherapy vs radiotherapy alone.